Kurma Partners
Kurma Partners is a management company specializing in the financing of innovation in healthcare and biotechnology.
Business Model:
Revenue: $12.7M
Employees: 11-50
Rankings
Detailed Kurma Partners Information
Kurma Partners was acquired by
Eurazeo.
The acquisition happend on 2021-09-24.
Details of the transaction were not public
Acquirer
Geographic Data
Address: 24, Rue Royale
City: Paris
State: île-de-france
Zip: 75008
Country: FR
Financial Info
Stage:
Raised Last:
$0
Raised Total:$175M
Social
Twitter
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Kurma Partners is a management company based in Paris, specializing in the financing of innovation in healthcare and biotechnology, from pre-creation to development capital. Kurma Partners, which manages the Kurma Biofund I, II funds and the Kurma Diagnostics fund, is one of the main players in the financing of therapeutic and medical innovations in Europe, particularly through links with many institutes. research and prestigious hospitals.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 10/2022 | DeepUll | Series B | 12.7M |
| 4/2014 | OxThera | Venture Round | 10.6M |
| 1/2022 | NaoX Technologies | Venture Round | 4.8M |
| 12/2014 | Xeltis | Series B | 33.5M |
| 1/2016 | Pharvaris | Series A | 16.3M |
| 7/2019 | AM Pharma | Series F | 130.1M |
| 11/2018 | Stilla Technologies | Series A | 18.3M |
| 4/2017 | DAMAE Medical | Seed Round | 0 |
| 9/2017 | DNA Script | Series A | 13.2M |
| 2/2020 | Stilla Technologies | Series B | 0 |
| 7/2019 | Amolyt Pharma | Series A | 0 |
| 12/2021 | Sunrise | Seed Round | 0 |
| 9/2018 | Asarina Pharma | Post-IPO Equity | 0 |
| 1/2020 | Sensome | Series B | 0 |
| 11/2017 | Step Pharma | Series A | 17M |
| 7/2014 | Step Pharma | Seed Round | 3.4M |
| 10/2021 | DNA Script | Series C | 0 |
| 11/2015 | BioSerenity | Seed Round | 3.2M |
| 11/2020 | Synendos Therapeutics | Series A | 0 |
| 7/2022 | Ganymed Robotics | Series B | 0 |
| 11/2015 | Advanced Perfusion Diagnostics | Seed Round | 1.7M |
| 11/2017 | Coave Therapeutics | Series B | 22M |
| 11/2020 | Corlieve Therapeutics | Seed Round | - |
| 6/2022 | Ermium Therapeutics | Series A | 0 |
| 9/2019 | Ermium Therapeutics | Series A | 7M |
| 1/2021 | IO Biotech | Series B | 0 |
| 6/2016 | DNA Script | Seed Round | 2.8M |
| 7/2017 | Cardiologs | Seed Round | 6.4M |
| 12/2021 | ARMGO,Pharma,Inc. | Series B | 0 |
| 12/2015 | Xeltis | Series B | 3.3M |
| 7/2017 | Sensome | Seed Round | 3.4M |
| 9/2019 | Tacalyx | Seed Round | 7.7M |
| 5/2017 | ImCheck Therapeutics | Series A | 21.9M |
| 5/2013 | STAT-Dx | Series B | 28.9M |
| 7/2020 | Vico Therapeutics | Series A | 31M |
| 9/2018 | Minoryx Therapeutics | Series B | 0 |
| 10/2017 | FeetMe | Seed Round | 2.3M |
| 11/2021 | Stilla Technologies | Debt Financing | 0 |
| 9/2019 | FeetMe | Series A | 10.4M |
| 11/2017 | Orphazyme | Post-IPO Equity | 0 |
| 12/2019 | ImCheck Therapeutics | Series B | 53.2M |
| 4/2016 | STAT-Dx | Series C | 0 |
| 3/2020 | AM Pharma | Venture Round | 25.4M |
| 11/2016 | OxThera | Series D | 34.1M |
| 5/2017 | Vivet Therapeutics | Series A | 41.2M |
| 12/2021 | Emergence Therapeutics | Series A | 0 |
| 6/2021 | Omnidoc | Seed Round | 3.7M |
| 7/2011 | ABM Pharma | Venture Round | 7.8M |
| 1/2015 | Orphazyme | Series B | 0 |
| 7/2013 | PathoQuest | Series B | 5M |
| 12/2014 | BliNK Biomedical | Series A | 5M |
| 12/2021 | Corteria Pharmaceuticals | Seed Round | 0 |
| 11/2020 | Lucine | Seed Round | 6.5M |
| 7/2020 | DeepUll | Series A | 3.9M |
| 9/2015 | Asceneuron | Series A | 30.8M |
| 3/2021 | Mila | Seed Round | 4.8M |
| 3/2011 | PathoQuest | Series A | 2.8M |
| 3/2017 | Orphazyme | Venture Round | 0 |
| 6/2018 | Sensome | Seed Round | 5.4M |
| 9/2019 | PathoQuest | Venture Round | 0 |
| 4/2011 | Asarina Pharma | Venture Round | - |
| 11/2016 | Asarina Pharma | Venture Round | 7.7M |
| 7/2018 | Safe Orthopaedics | Post-IPO Equity | 8.1M |
| 6/2022 | Charles.co | Seed Round | 0 |
| 1/2011 | Meiogenix | Series A | 1.6M |
| 11/2016 | Advanced Perfusion Diagnostics | Series A | 3M |
| 5/2021 | Arkhn | Series A | 4.9M |
| 1/2020 | Cardiologs | Series A | 15M |
| 5/2018 | PathoQuest | Venture Round | 0 |
| 3/2022 | FeetMe | Convertible Note | - |
| 10/2015 | Minoryx Therapeutics | Series A | 0 |
| 1/2023 | Amolyt Pharma | Series C | 0 |
| 5/2013 | Safe Orthopaedics | Venture Round | 2.6M |
| 3/2021 | Step Pharma | Series B | 0 |
| 11/2016 | Dynacure | Seed Round | 3.6M |
| 3/2021 | ARGOBIO | Funding Round | 0 |
| 2/2022 | DAMAE Medical | Series A | 5.7M |
| 7/2017 | Safe Orthopaedics | Post-IPO Equity | - |
| 5/2022 | Germitec SAS | Venture Round | 0 |
| 9/2021 | Amolyt Pharma | Series B | 0 |
| 7/2021 | Coave Therapeutics | Series B | 0 |
| 5/2021 | SmartCatch | Venture Round | 3.9M |
| 9/2019 | Pharvaris | Series B | 66M |
| 5/2019 | DNA Script | Series B | 38.5M |
| 12/2010 | Safe Orthopaedics | Series A | 7.9M |
| 7/2015 | PathoQuest | Venture Round | 0 |
| 11/2021 | PathoQuest | Series B | 17.4M |
| 6/2022 | ImCheck Therapeutics | Series C | 0 |
| 7/2018 | Dynacure | Series A | 55.2M |
| 4/2020 | Dynacure | Series C | 54.2M |
| 2/2021 | Medlumics | Venture Round | 21.8M |
| 11/2021 | PathoQuest | Series B | 0 |
| 9/2011 | AM Pharma | Series D | 39.9M |
| 9/2014 | AM Pharma | Series E | 15.8M |
| 11/2017 | Xeltis | Series C | 53M |
| 7/2022 | Ganymed Robotics | Series B | 0 |
| 6/2022 | Charles.co | Seed Round | 0 |
| 6/2022 | Ermium Therapeutics | Series A | 0 |
| 6/2022 | ImCheck Therapeutics | Series C | 0 |
| 5/2022 | Germitec SAS | Venture Round | 0 |
| 2/2022 | DAMAE Medical | Series A | 0 |
| 1/2022 | NaoX Technologies | Venture Round | 0 |
| 12/2021 | ARMGO,Pharma,Inc. | Series B | 0 |
| 12/2021 | Sunrise | Seed Round | 0 |
| 12/2021 | Corteria Pharmaceuticals | Seed Round | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
